Screener
Neuropace, Inc. NPCE EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Neuropace, Inc. in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Neuropace, Inc.’s 10-Q, filed August 11, 2026. Open the filing →
- Filed
- Aug 11, 2026, 4:33 PM EDT
- Fiscal quarter
- Q4 FY2030
- Calendar quarter
- Q4 2030
- Accession
- 0001528287-26-000030
FAQ
- What is Neuropace, Inc.'s EPS (diluted)?
- Neuropace, Inc. (NPCE) reported EPS (diluted) of -$0.18 in Q2 2026.
- How has Neuropace, Inc.'s EPS (diluted) changed year-over-year?
- Neuropace, Inc.'s EPS (diluted) increased by 30.8% year-over-year, from -$0.26 to -$0.18.
- What is the long-term trend for Neuropace, Inc.'s EPS (diluted)?
- Over 4 years (2021 to 2025), Neuropace, Inc.'s EPS (diluted) has grown at a -62.6% compound annual growth rate (CAGR), from -$33.91 to -$0.66.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Neuropace, Inc.'s eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude